PTAB grants inter partes review of China’s firm’s Alzheimer’s patent

The US Patent Trial and Appeal Board (PTAB) has given the go-ahead for an inter partes review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Genetics

Eli Lilly unit accuses Alzheimer's institute of ‘malicious’ patent prosecution

14 August 2019 Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, has taken the Alzheimer's Institute of America to court over its “malicious” prosecution of a patent infringement case.

Americas

AstraZeneca and Eli Lilly’s Alzheimer’s treatment to be fast tracked

23 August 2016 AstraZeneca and Eli Lilly have received US Food and Drug Administration fast track designation for the development of a treatment for Alzheimer’s.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

PTAB grants inter partes review of China’s firm’s Alzheimer’s patent

More on this story

Editor's picks

Editor's picks

More features